Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Spyre Therapeutics (SYRE)
NASDAQ:SYRE
RESEARCH TOOLSreports
Spyre Therapeutics (SYRE) Stock Price & Analysis
411 Followers
SYRE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.43 - $47.97
Previous Close$25.49
Volume216.47K
Average Volume (3M)578.83K
Market Cap
$1.31B
Enterprise Value$809.80M
Total Cash (Recent Filing)$484.64M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Aug 08, 2024EPS Estimate
-$0.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-71.38
Shares Outstanding50,782,384
10 Day Avg. Volume1,006,336
30 Day Avg. Volume578,829
Standard Deviation0.42
R-Squared0.14
Alpha-0.00306
Financial Highlights & Ratios
Price to Book (P/B)-1343.42
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-9.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.18K
Enterprise Value/Gross Profit914.00
Enterprise Value/Ebitda-2.59
Forecast
1Y Price Target
$45.00Price Target Upside74.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Spyre Therapeutics News
PremiumCompany Announcements
Spyre Therapeutics Announces Updated Share Structure
PremiumCompany Announcements
Spyre Therapeutics Expands Portfolio and Strengthens Leadership
Bulls Say, Bears Say
Bulls Say
Clinical ProgressSpyre has dosed the first healthy volunteers in its Phase 1 study of SPY001 (anti-α4β7 antibody), in development for inflammatory bowel disease (IBD).
Innovative PipelineSpyre Therapeutics' pipeline of half-life extended antibodies offering Q8-12W dosing could disrupt the inflammatory bowel disease (IBD) market, with a potential best-in-class subcutaneous (SC) dosing interval.
Market OpportunitySpyre has shown compelling preclinical data against validated targets, and its potential best-in-class dosing sets up for a big market opportunity in IBD.
Bears Say
Acquisition LikelihoodSince AbbVie is a large player in the IBD space, this makes them a less likely future acquirer for Spyre.
Competitive LandscapeThe agreement between AbbVie and FutureGen Biopharmaceutical adds competition within the TL1A space, one of Spyre's three disclosed pipeline targets.
Market PerformanceSYRE was down almost 20% while the S&P was up approximately 1%.
---
Ownership Overview
21.32% Insiders
12.35% Mutual Funds
43.10% Other Institutional Investors
23.22% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SYRE FAQ
What was Spyre Therapeutics’s price range in the past 12 months?
Spyre Therapeutics lowest stock price was $8.43 and its highest was $47.97 in the past 12 months.
What is Spyre Therapeutics’s market cap?
Currently, no data Available
When is Spyre Therapeutics’s upcoming earnings report date?
Spyre Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 30 days.
How were Spyre Therapeutics’s earnings last quarter?
Spyre Therapeutics released its earnings results on May 09, 2024. The company reported -$1.2 earnings per share for the quarter, missing the consensus estimate of -$1.049 by -$0.151.
Is Spyre Therapeutics overvalued?
According to Wall Street analysts Spyre Therapeutics’s price is currently Undervalued.
Does Spyre Therapeutics pay dividends?
Spyre Therapeutics does not currently pay dividends.
What is Spyre Therapeutics’s EPS estimate?
Spyre Therapeutics’s EPS estimate is -$0.95.
How many shares outstanding does Spyre Therapeutics have?
Spyre Therapeutics has 50,782,383 shares outstanding.
What happened to Spyre Therapeutics’s price movement after its last earnings report?
Spyre Therapeutics reported an EPS of -$1.2 in its last earnings report, missing expectations of -$1.049. Following the earnings report the stock price went up 4.945%.
Which hedge fund is a major shareholder of Spyre Therapeutics?
Among the largest hedge funds holding Spyre Therapeutics’s share is Perceptive Advisors LLC. It holds Spyre Therapeutics’s shares valued at 97M.
---
Spyre Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.00 (74.15% Upside)
$45.00 (74.15% Upside)
Hedge Fund Trend
Increased
By 461.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.8%
Last 30 Days >0.1%
Last 30 Days >0.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
137.11%
12-Months-Change
Fundamentals
Return on Equity
-391.81%
Trailing 12-Months
Asset Growth
829.60%
Trailing 12-Months
Company Description
Spyre Therapeutics
Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.
---
SYRE Stock 12 Month Forecast
Average Price Target
$45.00
▲(74.15% Upside)
Technical Analysis
Applied Therapeutics
―
Rocket Pharmaceuticals
―
Bioxcel Therapeutics
―
Crinetics Pharmaceuticals
―
Best Analysts Covering SYRE
1 Year
1 Year Success Rate
5/6 ratings generated profit
1 Year Average Return
+54.62%
reiterated a buy rating 4 months ago
Copying Alex Thompson CFA's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +54.62% per trade.
---